FILING ANALYSIS · THURSDAY, NOVEMBER 12
Serina Therapeutics, Inc. SER — 8-K: Results of Operations and Financial Condition
neutral
The company reported a net loss of $7.9 million and cash reserves of $19.4 million, with ongoing clinical trials for SER-252 in Parkinson's disease, but no significant surprises or quantified beats were disclosed in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →